London, Ontario-based Sernova designed its proprietary Cell Pouch System as an implantable and scalable medical device. It forms a natural environment in the body for the long-term survival and function of therapeutic cells. Those cells release necessary proteins or factors missing from the body to treat chronic diseases, including insulin-dependent diabetes.
The Phase 1/2 trial evaluates type 1 diabetes patients with severe hypoglycemia unawareness. Dr. Piotr Witkowski conducts the study at The University of Chicago. Results were presented at the American Diabetes Association (ADA) 83rd Scientific Sessions.
Sernova announced positive data from that trial in June 2022. That includes three patients achieving insulin independence.
Get the full story at our sister site, Drug Delivery Business News.
